Rosetta Biosoftware and Agendia to Deliver Diagnostic Utilities; Agendia Licenses the Rosetta Resolver System

"As we are now approaching 10,000 microarray hybridizationsassociated with extensive clinical data, the Rosetta Resolver systemis probably the only software product that can deal with the kind ofanalyses performed at our facilities. We are confident the Resolversystem will significantly enhance our gene expression analysis-baseddiagnostic services," said Dr. Laura van't Veer, chief operatingofficer of Agendia. "Our objective is to use the Resolver system todevelop and explore gene expression profiles in support of ourclients' expanding clinical research programs. In addition, we wouldalso like to incorporate Agendia's own diagnostics workflow into thesystem."

"The Resolver system's ability to support 21 CFR Part 11compliance greatly assured us that it is our product of choice for afully integrated diagnostics and research platform for gene expressiondata," added Prof. Dr. Rene Bernards, chief scientific officer ofAgendia and project consultant.

"Rosetta Biosoftware and Agendia will enable interoperabilitybetween the Resolver system and Agendia's clinical and gene expressiondatabase to support Agendia's research and development of diagnosticproducts and services," said Yelena Shevelenko, vice president andgeneral manager of Rosetta Biosoftware. "Agendia's unparalleledexpertise in the cancer diagnostics field adds significant value toour current and future business and research directions. Agendia'slicensing of the Resolver system represents the first time RosettaBiosoftware has signed an agreement with a company engaged in usinggene expression to diagnose disease." Shevelenko added, "The Resolversystem's flexibility and power enable it to seamlessly address newapplications and functional areas, permitting Rosetta Biosoftware tocontinue to meet the diverse needs of life science researchorganizations."

The Rosetta Resolver system is developed and supported by RosettaBiosoftware and is distributed exclusively by Agilent Technologies.

About Agendia

Agendia is a world leader in gene expression analysis-baseddiagnostics. The company focuses on the development andcommercialization of diagnostic tests using tumor gene expressionprofiling. Agendia was the first to commercialize a prognostic test --MammaPrint(R) -- that predicts the chance of breast cancer recurrence.Recently Agendia also added CupPrint(R) to its pipeline for theidentification of Cancers of Unknown Primary. Agendia maintains closeties with the Netherlands Cancer Institute (NKI), ensuring access tothe latest developments in cancer research. Next to the development ofnew cancer diagnostics, Agendia offers its expertise in finding newprospective gene expression profiles to companies focusing on new drugdevelopment in the area of oncology.

More information about Agendia BV is available at www.agendia.com.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage,retrieval, and analysis solution for gene expression data. The systemis ideal for life science research organizations that need to assesscompound specificity or toxicity, identify new genes or therapeutictargets or compare and analyze large databases of expression profiles.The Rosetta Resolver system combines flexibility and ease of use withhigh-performance algorithms to produce a comprehensive solution forrapid analysis of gene expression data. The Rosetta Resolver systemcan accept and analyze data from a wide variety of expressionprofiling formats, including Agilent DNA microarrays, and appliesRosetta Biosoftware's proprietary error models to yield qualitystatistics for every gene expression measurement within the system.These statistics are automatically leveraged by Rosetta Resolversystem analysis tools for optimal results.

Life science research organizations that have licensed the RosettaResolver system include many of the top pharmaceutical companies inthe world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb,GlaxoSmithKline and Merck & Co., Inc., as well as premier academicinstitutions such as the Harvard University Center for GenomicsResearch and California Institute of Technology. Additionalinformation about the Rosetta Resolver system can be found on theRosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutionsfor life science research. Its enterprise software solutions,including the Rosetta Resolver and Rosetta Elucidator systems, empowerlife scientists with advanced, scalable, and easy-to-use analysisplatforms that accelerate discovery research. Rosetta Biosoftware is abusiness unit of Rosetta Inpharmatics LLC, a wholly owned subsidiaryof Merck & Co., Inc. (NYSE: MRK). More information about RosettaBiosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as thatterm is defined in the Private Securities Litigation Reform Act of1995. These statements involve risks and uncertainties, which maycause results to differ materially from those set forth in thestatements. The forward-looking statements may include statementsregarding product development, product potential, or financialperformance. No forward-looking statement can be guaranteed, andactual results may differ materially from those projected. NeitherRosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligationto publicly update any forward-looking statement, whether as a resultof new information, future events, or otherwise. Forward-lookingstatements in this press release should be evaluated together with themany uncertainties that affect the business of Merck & Co., Inc.including, among others, the extent to which Rosetta Inpharmatics'technology platform can be used in drug discovery programs,uncertainty of market acceptance of Rosetta Inpharmatics'technologies, ability to compete against existing technologies, andthose mentioned in the cautionary statements in Item 1 of Merck's Form10-K for the year ended Dec. 31, 2004, and in its periodic reports onForm 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are registered trademarks ofRosetta Inpharmatics LLC.

MammaPrint and CupPrint are registered trademarks of Agendia BV.